NBI 1117570
Alternative Names: Dual M1/M4 agonist - Neurocrine Biosciences; Dual muscarinic M1/M4 agonist - Nxera Pharma; NBI-1117570; NBI-570Latest Information Update: 13 Oct 2025
At a glance
- Originator Sosei Heptares
- Developer Neurocrine Biosciences; Nxera Pharma
- Class Antipsychotics; Small molecules
- Mechanism of Action Muscarinic M1 receptor agonists; Muscarinic M4 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Schizophrenia
Most Recent Events
- 13 Oct 2025 NBI 1117570 is still in phase I trial for Schizophrenia (In volunteers) in the Netherlands (PO) (CTIS2023-508814-40-00)
- 15 May 2025 Neurocrine Biosciences completes a phase I trial in Schizophrenia (In volunteers) in the Netherlands (PO) (CTIS2023-508814-40-00)
- 14 Jan 2025 Neurocrine plans to initiate a phase II trail in schizophrenia, in the second half of 2025